Memorial Hospital Research Laboratories
The Charles Rudin Lab
Research

Physician-scientist Charles M. Rudin, Chief of the Thoracic Oncology Service, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials.

Featured News

Publications
Chow A, Uddin FZ, Liu M, Dobrin A, Nabet BY, Mangarin L, Lavin Y, Rizvi H, Tischfield SE, Quintanal-Villalonga A, Chan JM, et al. The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity. (2023)
People

Charles M. Rudin, MD, PhD
- Physician-scientist Charles Rudin focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models.
- MD, PhD, University of Chicago Pritzker School of Medicine
- [email protected]
- Email Address
- View physician profile
- Physician profile
Members



- Postdoctoral in Immunology from University of Sao Paulo / Memorial Sloan-Kettering Cancer Center
- PhD in Oncology from A. C. Camargo Hospital / MD Anderson Cancer Center
- MS in Oncology from Ludwig Institute for Cancer Research / A. C. Camargo Hospital











Graduate Student

Graduate Student

Co-Director, The Charles Rudin Lab

Senior Program Manager

Senior Research Assistant

Graduate Student

Research Fellow

Research Technician

Postdoctoral Fellow

Postdoctoral Fellow

Senior Research Technician

Graduate Student

Research Fellow

Graduate Student

Postdoctoral Fellow

Senior Research Technician

Research Fellow

Research Assistant




- Residency, Cornell University (Internal Medicine)
- MD, PhD, Columbia University
- BS, Stanford University

- BS, Northeastern University











Lab Alumni

Research Associate, Pfizer Inc.

Technical Application Liaison, Mission Bio

Assistant Professor, Director, Preclinical Therapeutics Program, Perlmutter Cancer Center, NYU Langone Health

Assistant Member

Postdoctoral Research Fellow, Harold Varmus Lab, WCMC

Senior Scientist, Drug Discovery Biology, Treeline Biosciences, Cambridge, MA

Senior Associate, Clarion Life Sciences

Medical Resident, Yale School of Medicine

Clinician-Scientist, Princess Margaret Cancer Centre and Assistant Professor of Radiation Oncology, University of Toronto

Lab Manager, University of Pennsylvania

Clinical Director in Oncology Early Development, Merck

Senior Global Development, Late Oncology Lung, Astra Zeneca

Assistant professor, Nagasaki University Hospital, Department of Respiratory Medicine

Senior Scientist, National Cancer Center, Singapore
Assistant Professor, McGill University

Technology Transfer Officer, Starfish Innovations

Research Technician

Assistant Professor, University of Cincinnati

Scientist 1 at Ratio Therapeutics
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Career Opportunities
Get in Touch
-
Lab Head Email
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Charles M. Rudin discloses the following relationships and financial interests:
-
Amgen
Professional Services and Activities -
AstraZeneca
Professional Services and Activities -
Bridge Medicines
Professional Services and Activities -
D2G Oncology
Professional Services and Activities
-
Daiichi Sankyo
Intellectual Property Rights -
Earli Inc.
Equity -
Harpoon Therapeutics, Inc.
Professional Services and Activities -
Jazz Pharmaceuticals
Professional Services and Activities
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].